

# CONCERT GENETICS GENETIC TESTING: PRENATAL AND PRECONCEPTION CARRIER SCREENING

---

See [Important Reminder](#) at the end of this policy for important regulatory and legal information

## OVERVIEW

There are more than 1,300 inherited recessive disorders (autosomal or X-linked) that affect 30 out of every 10,000 children. Some diseases have limited impact on either length or quality of life, while others are uniformly fatal in infancy or childhood. By definition, autosomal recessive disorders arise when both parents pass on disease-causing copies of genes to a child. X-linked recessive conditions arise when a disease-causing version of a gene is on the X-chromosome and is passed to a male child who only has one copy of the X-chromosome.

Carrier screening is performed to identify individuals at risk of having offspring with inherited recessive or X-linked single-gene disorders. Carriers are typically asymptomatic but can pass disease-causing variants to their offspring. The majority of professional societies recommend carrier screening prior to pregnancy. Risk-based carrier screening is performed in individuals who have an increased risk to be a carrier based on population carrier frequency, ethnicity, and/or family history.

Expanded carrier screening (ECS) involves screening individuals or couples for disorders in many genes simultaneously (up to 100s) by next-generation sequencing. ECS panels may screen for diseases that are present with increased frequency in specific populations, but also include a wide range of diseases for which the individual seeking testing is not at increased risk for positive carrier status. The conditions included on ECS panels are not standardized and the panels may include conditions that are not well understood and for which there are no existing professional guidelines.

“Negative” carrier screening results reduce, but do not eliminate, the chance of an individual being a carrier for the condition(s) screened. Therefore, there is still a “residual risk” of being a carrier for the condition(s) screened. The residual risk is the chance that the individual is still a carrier based on a normal/negative carrier screen. The residual risk will vary depending on which test is performed, how many mutations are included for each condition, the patient’s ethnicity, etc.

It is important to recognize that family history, ethnicity, and race are self-reported, and may not be completely accurate, particularly in multi-ethnic and multi-racial societies.

When one member of a couple is at high risk of being a carrier for a certain condition due to ancestry (e.g., Ashkenazi Jewish, French-Canadian, Cajun, etc.) or has a family history of a condition, the high-risk partner should be offered screening. If the high-risk partner is found to be a carrier, the other partner should then be offered screening.

Genetic counseling is strongly recommended for patients considering expanded carrier screening.

## POLICY REFERENCE TABLE

### Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2022, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

Please see the [Concert Genetics Platform](#) for a comprehensive list of registered tests

<a href="#">Criteria Sections</a>	Example Tests (Labs)	Common CPT Codes	Common ICD Codes	<a href="#">Ref</a>
<a href="#">Expanded Carrier Screening Panels</a>	Foresight Universal Panel Carrier Screen (Myriad Genetics)	81329, 81443	O09, Z13, Z31, Z34, Z36, Z84	2, 4
	Inheritest 500 Plus Panel (Labcorp) Comprehensive Carrier Screening (Invitae)	81443		

	GeneSeq Plus (Labcorp)	81336,81405,81408, 81479		
	QHerit™ Expanded Carrier Screen (Quest Diagnostics)	81243, 81443		
	Horizon 27 (Natera)	81243, 81257, 81329, 81443		
<a href="#">Basic Carrier Screening Panels (Cystic Fibrosis, Spinal Muscular Atrophy, Fragile X, Hemoglobinopathies, not more than 14 genes)</a>	Inheritest Core Panel (Labcorp)	81220, 81222, 81223, 81243, 81257, 81329, 81336	O09, Z13, Z31, Z34, Z36, Z84	2, 3
	Inheritest Carrier Screen, Society-guided Panel (14 Genes) (Labcorp)			
	Prenatal Carrier Panel (Quest Diagnostics)			
	Foresight Fundamental Panel (Myriad Genetics)			
	Core Carrier Screen (Invitae)			
<b><a href="#">Cystic Fibrosis Carrier Screening</a></b>				
<a href="#">CFTR Known Familial Variant Analysis</a>	CFTR Targeted Variants - Single Test (GeneDx)	81221	O09, Z13, Z31, Z36, Z83.49	3
<a href="#">CFTR Sequencing and/or Deletion/Duplication Analysis, or Mutation Panel</a>	Cystic Fibrosis Complete Rare Variant Analysis, Entire Gene Sequence (Quest Diagnostics)	81223		1
	Cystic Fibrosis Gene Deletion or Duplication (Quest Diagnostics)	81222		
	CFvantage Cystic Fibrosis Expanded Screen (Quest Diagnostics)	81220		
<a href="#">CFTR Intron 9 PolyT and TG Analysis (previously called Intron 8 polyT/TG Analysis)</a>	CFTR Intron 8 Poly-T Analysis (Quest Diagnostics)	81224		
<b><a href="#">Spinal Muscular Atrophy Carrier Screening</a></b>				
<a href="#">SMN1 Targeted Variant Analysis</a>	Spinal Muscular Atrophy - SMN1 Known Variant Testing (Nemours)	81337, 81403	O09, Z13, Z31, Z34,	3

	SMN1 Targeted Variant - 2 Variants Test (GeneDx)		Z36, Z84	
<a href="#">SMN1 Sequencing and/or Deletion/Duplication and SMN2 Deletion/Duplication Analysis</a>	Spinal Muscular Atrophy Carrier Test (Natera)	81329, 81336, 81401, 81405		3, 5
	Genomic Unity SMN1/2 Analysis (Variantyx Inc)	0236U		
<b><u>Fragile X Syndrome Carrier Screening</u></b>				
<a href="#">FMRI Repeat Analysis</a>	Fragile X Syndrome, PCR with Reflex to Southern Blot (Integrated Genetics)	81243, 81244	O09, Z13, Z31, Z34, Z36, Z84	3, 8, 9
	Fragile X Syndrome, PCR and Southern Blot Analysis (Labcorp)			
<b><u>Hemoglobinopathy Carrier Screening</u></b>				
<a href="#">HBA1, HBA2, or HBB Targeted Variant Analysis</a>	Alpha-Globin Common Mutation Analysis (Quest Diagnostics)	81257, 81258	O09, Z13, Z31, Z34, Z36, Z84	3
	HBA1 Targeted Variant-Single Test (GeneDx) HBA2 Targeted Variant-Single Test (GeneDx)			
	HBB Targeted Variant - Single Test (GeneDx)	81361, 81362		
<a href="#">HBA1, HBA2, or HBB Sequencing and/or Deletion/Duplication Analysis</a>	Alpha-Globin Gene Sequencing and Deletion/Duplication (Quest Diagnostics)	81259, 81269, 81363, 81364		
	HBA1 Deletion/Duplication (GeneDx) HBA2 Deletion/Duplication (GeneDx)			
	HBB Carrier-Full Gene Sequencing and Deletion/Duplication (Invitae)			
<b><u>Ashkenazi Jewish Carrier Panel Testing</u></b>				
<a href="#">Ashkenazi Jewish Carrier Panel Testing</a>	Ashkenazi Jewish Panel (11 Tests) (Quest Diagnostics)	81412	O09, Z13, Z31, Z34, Z36, Z84	3

<u>Duchenne and Becker Muscular Dystrophy Carrier Screening</u>				
<a href="#"><u>DMD Targeted Variant Analysis</u></a>	DMD Targeted Variants - Single Test (GeneDx)	814793	O09, Z13, Z31, Z34, Z36, Z84	6
<a href="#"><u>DMD Sequencing and/or Deletion/Duplication Analysis</u></a>	Duchenne/Becker MD (DMD) Gene Sequencing (GeneDx)	81161, 81408		7
	Duchenne/Becker MD (DMD) Del/Dup (GeneDx)			
	Genomic Unity DMD Gene Analysis (Variantyx)	0218U		
<u>General Criteria for Targeted Carrier Screening</u>				
<a href="#"><u>General Criteria for Targeted Carrier Screening</u></a>	Varies	81174, 81190, 81200, 81205, 81209, 81242, 81247, 81248, 81250, 81251, 81253, 81254, 81289, 81401, 81402, 81403, 81404, 81405, 81406, 81407, 81408	Z14, Z15, Z31	2, 3

## OTHER RELATED POLICIES

This policy document provides criteria for Prenatal and Preconception Carrier Screening. Please refer to:

- **Genetic Testing: Prenatal Diagnosis (via amniocentesis, CVS, or PUBS) and Pregnancy Loss** for coverage related to prenatal and pregnancy loss diagnostic genetic testing intended to diagnose genetic conditions following amniocentesis, chorionic villus sampling, or pregnancy loss.
- **Genetic Testing: Noninvasive Prenatal Screening (NIPS)** for criteria related to prenatal cell-free DNA screening tests.
- **Genetic Testing: Preimplantation Genetic Testing** for criteria related to genetic testing of embryos prior to in vitro fertilization.

- **Genetic Testing: Multisystem Inherited Disorders, Intellectual Disability and Developmental Delay** for criteria related to suspected multisystem genetic conditions in the postnatal period.
- **Genetic Testing: Hearing Loss** for coverage related to diagnostic genetic testing for hereditary hearing loss.
- **Genetic Testing: Hematologic Conditions (non-cancerous)** for coverage related to diagnostic genetic testing for alpha-thalassemia and other hemoglobinopathies.
- **Genetic Testing: Metabolic, Endocrine, and Mitochondrial Disorders** for coverage related to diagnostic genetic testing for mitochondrial and other disorders.
- **Genetic Testing: General Approach to Genetic and Molecular Testing** for criteria related to carrier screening that is not specifically discussed in this or other non-general policies.

## CRITERIA

It is the policy of health plans affiliated with Centene Corporation® that the specific genetic testing noted below is **medically necessary** when meeting the related criteria:

### EXPANDED CARRIER SCREENING PANELS

- I. Expanded carrier screening panels (81243, 81257, 81329, 81336, 81405, 81408, 81479, 81443\*) may be considered **medically necessary** when:
  - A. The member/enrollee is considering pregnancy or is currently pregnant\*\*, **AND**
  - B. The panel includes the genes *CFTR* and *SMN1*.
- II. Expanded carrier screening panels (81243, 81257, 81329, 81336, 81405, 81408, 81479, 81443\*) are considered **investigational** for all other indications.

\*Fragile X (81243) and spinal muscular atrophy (SMA) (81329) carrier screening may be billed along with 81443 if performed separately from the remainder of the panel per CPT Code Book Guidelines.

\*\*ACMG recommends follow-up screening for the partner of the member/enrollee that is pregnant or considering pregnancy via analysis of the same gene that has the pathogenic or LP variant as identified in the member/enrollee. Therefore, expanded carrier screening panels are not recommended to be completed by both reproductive partners in tandem.

[back to top](#)

## **BASIC CARRIER SCREENING PANELS (Cystic fibrosis, Spinal Muscular Atrophy, Fragile X, Hemoglobinopathies, not more than 14 genes)**

- I. Basic carrier screening panels (*CFTR*, *SMN1/2*, *FMRI*, *HBB/HBA1/HBA2*, but not more than 14 genes) (81220, 81222, 81223, 81243, 81257, 81329, 81336) may be considered **medically necessary** when:
  - A. The member/enrollee is considering pregnancy or is currently pregnant\*, **AND**
  - B. The panel includes the genes *CFTR* and *SMN1*.
- II. Basic carrier screening panels (*CFTR*, *SMN1/2*, *FMRI*, *HBB/HBA1/HBA2*, but not more than 14 genes) (81220, 81222, 81223, 81329, 81243, 81257, 81329, 81336) are considered investigational for all other indications.

\*ACMG recommends follow-up screening for the partner of the member/enrollee that is pregnant or considering pregnancy via analysis of the same gene that has the pathogenic or LP variant as identified in the member/enrollee. Therefore, basic carrier screening panels are not recommended to be completed by both reproductive partners in tandem.

[back to top](#)

## **CYSTIC FIBROSIS CARRIER SCREENING**

### ***CFTR* Known Familial Variant Analysis**

- I. Cystic fibrosis carrier screening via *CFTR* targeted mutation analysis for a known familial mutation (81221) may be considered **medically necessary** when:
  - A. The member/enrollee and/or the member/enrollee's reproductive partner is considering pregnancy or is currently pregnant, **AND**
  - B. The member/enrollee has a [close relative](#) with a known pathogenic or likely pathogenic variant in *CFTR*.
- II. Cystic fibrosis carrier screening via *CFTR* targeted mutation analysis for a known familial mutation (81221) is considered **investigational** for all other indications.

## **CFTR Sequencing, Deletion/Duplication Analysis, or Mutation Panel**

- I. Cystic fibrosis carrier screening via *CFTR* sequencing (81223), deletion/duplication analysis (81222), or a mutation panel (81220) using at a minimum the ACMG-100 variant panel, may be considered **medically necessary** when:
  - A. The member/enrollee and/or the member/enrollee's reproductive partner is considering pregnancy or is currently pregnant, **OR**
  - B. The member/enrollee's reproductive partner is a known carrier for cystic fibrosis.
- II. Cystic fibrosis carrier screening via *CFTR* sequencing (81223), deletion/duplication analysis (81222), or a mutation panel (81220) using at a minimum the ACMG-100 variant panel, is considered **investigational** for all other indications.

## **CFTR Intron 9 PolyT and TG Analysis (previously called Intron 8 polyT/TG Analysis)**

- I. Analysis of the *CFTR* intron 9 polyT and TG regions (81224) for cystic fibrosis carrier screening may be considered **medically necessary** when:
  - A. The member/enrollee and/or the member/enrollee's reproductive partner is considering pregnancy or is currently pregnant, **AND**
  - B. The member/enrollee is known to have an R117H variant in the *CFTR* gene.
- II. Analysis of the *CFTR* intron 9 polyT and TG regions (81224) for cystic fibrosis carrier screening is considered **investigational** for all other indications.

**Note:** Refer to *Genetic Testing for Multisystem Inherited Disorders, Intellectual Disability and Developmental Delay* for criteria for genetic testing to establish a diagnosis of cystic fibrosis.

[back to top](#)

## **SPINAL MUSCULAR ATROPHY CARRIER SCREENING**

### **SMNI Targeted Variant Analysis**

- I. Spinal muscular atrophy (SMA) carrier screening via *SMNI* targeted variant analysis (81337, 81403) may be considered **medically necessary** when:
  - A. The member/enrollee and/or the member/enrollee's reproductive partner is considering pregnancy or is currently pregnant, **AND**



- B. The member/enrollee has a [close relative](#) with a known pathogenic or likely pathogenic variant in *SMN1*.
- II. Spinal muscular atrophy (SMA) carrier screening via *SMN1* targeted variant analysis (81337, 81403) is considered **investigational** for all other indications.

### ***SMN1* Sequencing and/or Deletion/Duplication and *SMN2* Deletion/Duplication Analysis**

- I. Spinal muscular atrophy (SMA) carrier screening via *SMN1* sequencing and/or deletion/duplication analysis and *SMN2* deletion/duplication analysis (81329, 81336, 81401, 81405, 0236U) is considered **medically necessary** when:
  - A. The member/enrollee and/or member/enrollee's reproductive partner is considering pregnancy or is currently pregnant, **OR**
  - B. The member/enrollee's reproductive partner is a known carrier for spinal muscular atrophy.
- II. Spinal muscular atrophy (SMA) carrier screening via *SMN1* sequencing and/or deletion/duplication analysis and *SMN2* deletion/duplication analysis (81329, 81336, 81401, 81405, 0236U) is considered **investigational** for all other indications.

**Note:** Refer to *Genetic Testing for Epilepsy, Neuromuscular, and Neurodegenerative Disorders* for criteria for genetic testing to establish a diagnosis of spinal muscular atrophy (SMA).

[back to top](#)

## **FRAGILE X SYNDROME CARRIER SCREENING**

### ***FMRI* Repeat Analysis**

- I. Fragile X carrier screening via *FMRI* CGG-trinucleotide repeat analysis (81243, 81244) may be considered **medically necessary** when:
  - A. The member/enrollee has been diagnosed with premature ovarian insufficiency or elevated follicle-stimulating hormone level before age 40 years, **OR**
  - B. The member/enrollee is considering a pregnancy or is currently pregnant, **AND**
    - 1. The member/enrollee has one of the following:

- a) [Close relative](#) with Fragile X syndrome (i.e., close relative has more than 200 CGG repeats in the *FMRI* gene), **OR**
  - b) [Close relative](#) who is a known carrier for Fragile X syndrome (i.e., close relative has between 55-200 CGG repeats in the *FMRI* gene), **OR**
  - c) [Close relative](#) with unexplained intellectual disability, developmental delay, or autism spectrum disorder, **OR**
  - d) [Close relative](#) diagnosed with premature ovarian insufficiency or elevated follicle-stimulating hormone level before age 40 years.
- II. Fragile X carrier screening via *FMRI* CGG-trinucleotide repeat analysis (81243, 81244) is considered **investigational** for all other indications.

**Note:** Refer to *Genetic Testing for Multisystem Inherited Disorders, Intellectual Disability and Developmental Delay* for criteria for genetic testing to establish a diagnosis of fragile X syndrome.

[back to top](#)

## HEMOGLOBINOPATHY CARRIER SCREENING

### *HBA1*, *HBA2*, or *HBB* Targeted Variant Analysis

- I. Hemoglobinopathy carrier screening via *HBA1*, *HBA2* (81257, 81258), or *HBB* (81361, 81362) targeted variant analysis may be considered **medically necessary** when:
  - A. The member/enrollee and/or the member/enrollee's reproductive partner is considering pregnancy or is currently pregnant, **AND**
  - B. The member/enrollee meets one of the following:
    1. The member/enrollee has a [close relative](#) with a known pathogenic or likely pathogenic variant in *HBA1*, *HBA2*, or *HBB*, **OR**
    2. The member/enrollee's reproductive partner is a known carrier of a pathogenic or likely pathogenic variant in *HBA1*, *HBA2*, or *HBB*, **OR**
    3. The member/enrollee's hematologic screening results (e.g., MCV, MCH, CBC, hemoglobin electrophoresis, or dichlorophenol indophenol (DCIP)) are suggestive of or do not conclusively rule out a hemoglobinopathy.

- II. Hemoglobinopathy carrier screening via *HBA1*, *HBA2* (81257, 81258), or *HBB* (81361, 81362) targeted variant analysis is considered **investigational** for all other indications.

### ***HBA1*, *HBA2*, or *HBB* Sequencing and/or Deletion/Duplication Analysis**

- I. Hemoglobinopathy carrier screening via *HBA1*, *HBA2* (81259, 81269), or *HBB* (81363, 81364) sequencing and/or deletion/duplication analysis may be considered medically necessary when:
  - A. The member/enrollee and/or the member/enrollee's reproductive partner is considering pregnancy or is currently pregnant, **AND**
  - B. The member/enrollee's hematologic screening results (e.g., MCV, MCH, CBC, hemoglobin electrophoresis, or dichlorophenol indophenol (DCIP)) are suggestive of, or do not conclusively rule out, a hemoglobinopathy.
- II. Hemoglobinopathy carrier screening via *HBA1*, *HBA2* (81259, 81269), or *HBB* (81363, 81364) sequencing and/or duplication analysis is considered **investigational** for all other indications.

**Note:** Refer to *Genetic Testing for Hematologic Disorders (non-cancerous)* for criteria for genetic testing to establish a diagnosis of a hemoglobinopathy.

[back to top](#)

## **ASHKENAZI JEWISH CARRIER PANEL TESTING**

- I. Ashkenazi Jewish carrier panel testing (81412) may be considered **medically necessary** when:
  - A. The member/enrollee and/or the member/enrollee's reproductive partner is considering pregnancy or is currently pregnant, **AND**
  - B. The member/enrollee is of Ashkenazi Jewish ancestry, **AND**
  - C. The panel includes, at a minimum, screening for carrier status for genetic conditions associated with the following genes, as recommended by the American College of Medical Genetics (ACMG):

1. Tay Sachs disease (HEXA)
2. Canavan disease (ASPA)
3. Cystic fibrosis (CFTR)
4. Familial dysautonomia (ELP1)
5. Bloom syndrome (BLM)
6. Fanconi anemia (FANCC)
7. Niemann-Pick disease type A (SMPD1)
8. Gaucher disease Type 1 (GBA)
9. Mucopolysaccharidosis IV (MCOLN1)
10. Glycogen storage disease type I
11. Joubert syndrome
12. Maple syrup urine disease
13. Usher syndrome

**Note:** If only one partner is of Ashkenazi Jewish ancestry, then testing of that partner is considered medically necessary. Testing of the other partner is considered medically necessary only if the result of testing of the Ashkenazi Jewish partner is positive.

[back to top](#)

## **DUCHENNE AND BECKER MUSCULAR DYSTROPHY CARRIER SCREENING**

### ***DMD* Targeted Variant Analysis**

- I. Duchenne and Becker muscular dystrophy carrier screening via *DMD* targeted variant analysis (81479) may be considered **medically necessary** when:
  - A. The member/enrollee is considering pregnancy or is currently pregnant, **AND**
  - B. The member/enrollee has a [close relative](#) with a known pathogenic or likely pathogenic variant in *DMD*.
- II. Duchenne and Becker muscular dystrophy carrier screening via *DMD* targeted variant analysis (81479) is considered **investigational** for all other indications.

### ***DMD* Sequencing and/or Deletion/Duplication Analysis**

- I. Duchenne and Becker muscular dystrophy carrier screening via *DMD* sequencing and/or deletion/duplication analysis (81161, 81408, 0218U) may be considered **medically necessary** when:

- A. The member/enrollee is considering pregnancy or is currently pregnant, **AND**
  - B. The member/enrollee has a first- or second-degree relative diagnosed with Duchenne or Becker muscular dystrophy.
- II. Duchenne and Becker muscular dystrophy carrier screening via *DMD* sequencing and/or deletion/duplication analysis (81161, 81408, 0218U) is considered **investigational** for all other indications.

**Note:** Refer to *Genetic Testing for Epilepsy, Neuromuscular, and Neurodegenerative Disorders* for criteria for genetic testing to establish a diagnosis of Duchenne or Becker muscular dystrophy.

[back to top](#)

## GENERAL CRITERIA FOR TARGETED CARRIER SCREENING

**NOTE:** Each section in the policy reference table includes specific criteria. For any prenatal or preconception carrier screening test that does not have specific criteria above, refer to the following criteria to assess for medical necessity.

Targeted carrier screening is defined as a test that screens for a known mutation in one gene associated with a specific genetic condition.

- I. Carrier screening for a genetic disorder (81174, 81190, 81200, 81205, 81209, 81242, 81247, 81248, 81250, 81251, 81253, 81254, 81289, 81401, 81402, 81403, 81404, 81405, 81406, 81407, 81408) may be considered **medically necessary** when:
  - A. The member/enrollee is considering pregnancy or is currently pregnant, **AND**
  - B. The genetic disorder is a recessive condition with a childhood onset, **AND**
  - C. One of the following:
    - 1. The member/enrollee has a close relative with a known pathogenic or likely pathogenic variant associated with the disorder, **OR**
    - 2. The member/enrollee's reproductive partner is a carrier for the genetic disorder, **OR**
    - 3. The member/enrollee or the member/enrollee's reproductive partner are members of a population known to have a carrier rate of 1% or higher for the genetic condition, **OR**

4. The member/enrollee or the member/enrollee’s reproductive partner has a [first- or second-degree](#) relative who is affected with the genetic disorder.
- II. Carrier screening for a genetic disorder (81174, 81190, 81200, 81205, 81209, 81242, 81247, 81248, 81250, 81251, 81253, 81254, 81289, 81401, 81402, 81403, 81404, 81405, 81406, 81407, 81408) is considered **investigational** when the member/enrollee does not meet any criteria above.

[back to top](#)

## NOTES AND DEFINITIONS

1. **Close relatives** include first, second, and third degree relatives on the same side of the family:
  - a. **First-degree relatives** are parents, siblings, and children
  - b. **Second-degree relatives** are grandparents, aunts, uncles, nieces, nephews, grandchildren, and half siblings
  - c. **Third-degree relatives** are great grandparents, great aunts, great uncles, great grandchildren, and first cousins.

## BACKGROUND AND RATIONALE

### Expanded Carrier Screening Panels

*American College of Obstetricians and Gynecologists (ACOG)*

The American College of Obstetricians and Gynecologists (ACOG) published practice bulletin No. 690 (2017, reaffirmed 2023) regarding “Carrier Screening in the Age of Genomic Medicine”, which made the following recommendations: “Ethnic-specific, panethnic, and expanded carrier screening are acceptable strategies for pre pregnancy and prenatal carrier screening. Each obstetrician–gynecologist or other health care provider or practice should establish a standard approach that is consistently offered to and discussed with each patient, ideally before pregnancy. After counseling, a patient may decline any or all carrier screening.” (p. e35)

It was also recommended that: “All patients who are considering pregnancy or are already pregnant, regardless of screening strategy and ethnicity, should be offered carrier screening for cystic fibrosis and spinal muscular atrophy, as well as a complete blood count and screening for thalassemias and hemoglobinopathies.” (p. e35)

*American College of Medical Genetics and Genomics (ACMG):*

ACMG published a practice resource (2021) regarding screening for autosomal recessive and X-linked conditions during pregnancy and preconception, which includes the following recommendations:

- The phrase “expanded carrier screening” be replaced by “carrier screening”.
- Adopting a more precise tiered system based on carrier frequency (p. 1796)
  - Tier 1: CF + SMA + Risk Based Screening
  - Tier 2: 1/100 carrier frequency or higher (includes Tier 1)
  - Tier 3: 1/200 carrier frequency or higher (includes Tier 2) includes X-linked conditions
  - Tier 4: 1/200 carrier frequency or higher (includes Tier 3) genes/condition will vary by lab
- All pregnant patients and those planning a pregnancy should be offered Tier 3 carrier screening. (p. 1797)
- Tier 4 screening should be considered (p. 1797):
  - When a pregnancy stems from a known or possible consanguineous relationship (second cousins or closer)
  - When a family or personal medical history warrants.
- Reproductive partners of pregnant patients and those planning a pregnancy may be offered Tier 3 carrier screening for autosomal recessive conditions when carrier screening is performed simultaneously with their partner.
- Additionally, ACMG recommends follow-up screening of the partner with analysis of the same gene that has the pathogenic or LP variant as that identified in the partner. (p. 1804)

ACMG does not recommend:

- Offering Tier 1 and/or Tier 2 screening without Tier 3, because these do not provide equitable evaluation of all racial/ethnic groups.
- Routine offering of Tier 4 panels. (p. 1797)

**Basic Carrier Screening Panels (Cystic Fibrosis, Spinal Muscular Atrophy, Fragile X, Hemoglobinopathies, not more than 14 genes)**

*American College of Obstetricians and Gynecologists (ACOG)*

ACOG published practice bulletin No. 691 (March 2017, reaffirmed 2020), which includes the following recommendations related to carrier screening (p. 598):

- Screening for spinal muscular atrophy should be offered to all women who are considering pregnancy or are currently pregnant.
- Cystic fibrosis carrier screening should be offered to all women who are considering pregnancy or are currently pregnant.

ACOG published practice bulletin No. 690 (March 2017, reaffirmed 2020), which includes the following recommendations related to carrier screening (p. e35):

All patients who are considering pregnancy or are already pregnant, regardless of screening strategy and ethnicity, should be offered carrier screening for cystic fibrosis and spinal muscular atrophy, as well as a complete blood count and screening for thalassemias and hemoglobinopathies.

## **CYSTIC FIBROSIS CARRIER SCREENING**

### ***CFTR* Known Familial Analysis**

ACOG published practice bulletin No. 691 (March 2017, reaffirmed 2020) and the following recommendations related to carrier screening:

Cystic fibrosis carrier screening should be offered to all women who are considering pregnancy or are currently pregnant. When both partners are unaffected, but one or both has a family history of cystic fibrosis, genetic counseling and medical record review should be performed to determine if *CFTR* mutation analysis in the affected family member is available. Carrier screening should be offered for both partners, with attention to ensure that the familial mutation is included in the assessment. (p. 598)

### ***CFTR* Sequencing and/or Deletion/Duplication Analysis, or Mutation Panel**

*American College of Medical Genetics and Genomics (ACMG)*

In their 2023 position statement for *CFTR* variant testing, the American College of Medical Genetics and Genomics (ACMG) recommends a minimum number of 100 variants tested in the *CFTR* gene if carrier testing is pursued: “The new *CFTR* variant set [n=100; see p. 6] represents



an updated minimum recommended variant set for CF [cystic fibrosis] carrier screening, and this new set now supersedes the previous set of 23 CFTR variants recommended by the ACMG.” (p. 7)

### **CFTR Intron 9 PolyT and TG Analysis (previously called Intron 8 polyT/TG Analysis)**

*American College of Medical Genetics and Genomics (ACMG)*

In their 2020 technical standard for *CFTR* variant testing, the American College of Medical Genetics and Genomics (ACMG) recommends that, for all prenatal, postnatal, and adult diagnostic testing indications for *CFTR*, the R117H status as well as the results from at least the associated polyT tract be reported. For all adult carrier screening indications for *CFTR*, polyT status should be reported when the R117H variant is detected; laboratories may also want to consider reporting the results from the associated polyT tract in the partner of an individual who had a pathogenic or likely pathogenic variant detected during screening. (p. 12)

## **SPINAL MUSCULAR ATROPHY CARRIER SCREENING**

### **SMN1 Targeted Variant Analysis**

*American College of Obstetricians and Gynecologists (ACOG)*

The American College of Obstetricians and Gynecologists (ACOG) published practice bulletin No. 691 (2017) regarding “Carrier Screening for Genetic Conditions”, which made the following recommendations (p. 597-598):

When an individual is found to be a carrier for a genetic condition, the individual’s relatives are at risk of carrying the same mutation. Individuals with a positive family history of a genetic condition should be offered carrier screening for the specific condition and may benefit from genetic counseling.

### **SMN1 Sequencing and/or Deletion/Duplication and SMN2 Deletion/Duplication Analysis**

*American College of Obstetricians and Gynecologists (ACOG)*

The American College of Obstetricians and Gynecologists (ACOG) published practice bulletin No. 691 (March 2017, reaffirmed 2020) and the following recommendations (p. 598):

- Screening for spinal muscular atrophy should be offered to all women who are considering pregnancy or are currently pregnant.
- In patients with a family history of spinal muscular atrophy, molecular testing reports of the affected individual and carrier testing of the related parent should be reviewed, if possible, before testing. If the reports are not available, *SMNI* deletion testing should be recommended for the low-risk partner.

*American College of Medical Genetics and Genomics (ACMG)*

The American College of Medical Genetics and Genomics recommended the following on carrier screening for spinal muscular atrophy (Prior, et al, 2008):

Because SMA is present in all populations, carrier testing should be offered to all couples regardless of race or ethnicity. Ideally, the testing should be offered before conception or early in pregnancy. The primary goal is to allow carriers to make informed reproductive choices. (p. 841)

## **FRAGILE X SYNDROME CARRIER SCREENING**

### ***FMRI Repeat Analysis***

*American College of Obstetricians and Gynecologists (ACOG)*

The American College of Obstetricians and Gynecologists (ACOG) published practice bulletin No. 691 (2017, reaffirmed in 2020) regarding “Carrier Screening for Genetic Conditions”, which made the following recommendations (p. 2):

- Fragile X premutation carrier screening is recommended for women with a family history of fragile X-related disorders or intellectual disability suggestive of fragile X syndrome and who are considering pregnancy or are currently pregnant.
- If a woman has unexplained ovarian insufficiency or failure or an elevated follicle-stimulating hormone level before age 40 years, fragile X carrier screening is recommended to determine whether she has an *FMRI* premutation.
- All identified individuals with intermediate results and carriers of a fragile X premutation or full mutation should be provided follow-up genetic counseling to discuss the risk to their offspring of inheriting an expanded full-mutation fragile X allele and to discuss fragile X-associated disorders (premature ovarian insufficiency and fragile X tremor/ataxia syndrome).
- Prenatal diagnostic testing for fragile X syndrome should be offered to known carriers of the fragile X premutation or full mutation.

*American College of Medical Genetics and Genomics (ACMG)*

ACMG published practice guidelines for carrier screening for Fragile X syndrome (2005), which recommended that Fragile X syndrome carrier testing should be offered to individuals with the following:

- Individuals seeking reproductive counseling who have (a) a family history of fragile X syndrome or (b) a family history of undiagnosed mental retardation.
- Women who are experiencing reproductive or fertility problems associated with elevated follicle stimulating hormone (FSH) levels, especially if they have (a) a family history of premature ovarian failure, (b) a family history of fragile X syndrome, or (c) male or female relatives with undiagnosed mental retardation. (p. 586)

*American College of Obstetricians and Gynecologists (ACOG)*

ACOG published practice bulletin No. 605 (July 2014, reaffirmed 2021), which states the following:

“If a woman has a personal or family history of ovarian failure or an elevated follicle-stimulating hormone (FSH) level before age 40 years without a known cause, fragile X premutation carrier testing should be offered”. (p. 194)

## **HEMOGLOBINOPATHY CARRIER SCREENING**

### ***HBA1, HBA2, or HBB Targeted Variant Analysis***

*American College of Obstetricians and Gynecologists (ACOG)*

ACOG published practice bulletin No. 691 (March 2017, reaffirmed 2020) and following recommendations related to carrier screening (p. 597):

If an individual is found to be a carrier for a specific condition, the individual’s reproductive partner should be offered testing in order to receive informed genetic counseling about potential reproductive outcomes. Additionally, when an individual is found to be a carrier of a genetic condition, the individual’s relatives are at risk of carrying the same mutation. The patient should be encouraged to inform his or her relatives of the risk and the availability of carrier screening. (p. 597)

## ***HBA1, HBA2, or HBB Sequencing and/or Deletion/Duplication Analysis***

*American College of Obstetricians and Gynecologists (ACOG)*

ACOG published practice bulletin No. 691 (March 2017, reaffirmed 2020) and following recommendations related to carrier screening (p. 598):

- A complete blood count with red blood cell indices should be performed in all women who are currently pregnant to assess not only their risk of anemia but also to allow assessment for risk of a hemoglobinopathy. Ideally, this testing also should be offered to women before pregnancy.
- A hemoglobin electrophoresis should be performed in addition to a complete blood count if there is suspicion of hemoglobinopathy based on ethnicity (African, Mediterranean, Middle Eastern, Southeast Asian, or West Indian descent). If red blood cell indices indicate a low mean corpuscular hemoglobin or mean corpuscular volume, hemoglobin electrophoresis also should be performed.
- Beta-thalassemia is associated with elevated hemoglobin F and elevated hemoglobin A2 levels [identified on hemoglobin electrophoresis]. (p.9)
- Neither hemoglobin electrophoresis nor solubility testing can identify individuals with alpha-thalassemia trait; only molecular genetic testing can identify this condition. If the mean corpuscular volume is below normal, iron deficiency anemia has been excluded, and the hemoglobin electrophoresis is not consistent with beta-thalassemia trait (ie. there is no elevation of HbA2 or HbF), then DNA-based testing should be used to detect alpha globin gene deletions characteristic of alpha-thalassemia. (p.9)

## **Ashkenazi Jewish Carrier Panel Testing**

*American College of Obstetricians and Gynecologists (ACOG)* ACOG published practice bulletin No. 691 (2017), which provided carrier screening guidelines in individuals of Eastern and Central European Jewish descent (i.e., Ashkenazi Jewish). Specifically, they made the following recommendations:

- Cystic fibrosis, Canavan disease, familial dysautonomia, and Tay-Sachs disease carrier screening should be offered to all Ashkenazi Jewish individuals who are pregnant or considering pregnancy
- Consider carrier screening for Fanconi anemia (Group C), Niemann-Pick (Type A), Bloom syndrome, mucopolidosis IV, glycogen storage disease type I, Joubert syndrome, maple syrup urine disease, Usher syndrome, and Gaucher disease. (p. 11-13)

- When only one partner is of Ashkenazi Jewish descent, that individual should be offered screening first. If it is determined that this individual is a carrier, the other partner should be offered screening. However, the couple should be informed that the carrier frequency and the detection rate in non-Jewish individuals are unknown for most of these disorders, except for Tay–Sachs disease and cystic fibrosis. Therefore, it is difficult to accurately predict the couple’s risk of having a child with the disorder. (p. 3)

## **DUCHENNE AND BECKER MUSCULAR DYSTROPHY CARRIER SCREENING**

### ***DMD Targeted Variant Analysis***

*GeneReviews: Dystrophinopathies*

GeneReviews is an expert-authored review of current literature on a genetic disease and goes through a rigorous editing and peer review process before being published online.

Per GeneReviews, it is appropriate to evaluate at-risk female family members (i.e., the sisters or maternal female relatives of an affected male and first-degree relatives of a known or possible heterozygous female) in order to identify as early as possible heterozygous females who would benefit from cardiac surveillance. Evaluations can include molecular genetic testing if the *DMD* pathogenic variant in the family is known.

### ***DMD Sequencing and/or Deletion/Duplication Analysis***

*European Molecular Genetics Quality Network (EMQN)*

EMQN published best practice guidelines for genetic testing in dystrophinopathies (2020), which included the following in regard to carrier testing in females:

“When the familial pathogenic variant is unknown and an affected male is not available to be tested, female relatives at risk of being carriers should be offered the full cohort of level 1 and 2 genetic testing (i.e., CNV analysis and sequencing) since these two approaches are cost effective and offer ~99% sensitivity.” (p. 1147)

### **General Criteria for Targeted Carrier Screening**

*American College of Obstetricians and Gynecologists (ACOG)*

ACOG published practice bulletin No. 690 (March 2017, reaffirmed 2023), which includes the following recommendations related to carrier screening:

- Given the multitude of conditions that can be included in expanded carrier screening panels, the disorders selected for inclusion should meet several of the following consensus-determined criteria: have a carrier frequency of 1 in 100 or greater, have a well-defined phenotype, have a detrimental effect on quality of life, cause cognitive or physical impairment, require surgical or medical intervention, or have an onset early in life. Additionally, screened conditions should be able to be diagnosed prenatally and may afford opportunities for antenatal intervention to improve perinatal outcomes, changes to delivery management to optimize newborn and infant outcomes, and education of the parents about special care needs after birth.
- Carrier screening panels should not include conditions primarily associated with a disease of adult onset. (p. e36)

ACOG published practice bulletin No. 691 (March 2017), which includes the following recommendations related to carrier screening:

- Information about carrier screening should be provided to every pregnant woman.
- Carrier screening and counseling ideally should be performed before pregnancy because this enables couples to learn about their reproductive risk and consider the most complete range of reproductive options. A patient may decline any or all screening.
- When an individual is found to be a carrier for a genetic condition, his or her relatives are at risk of carrying the same mutation. The patient should be encouraged to inform his or her relatives of the risk and the availability of carrier screening.
- If an individual is found to be a carrier for a specific condition, the patient’s reproductive partner should be offered testing in order to receive informed genetic counseling about potential reproductive outcomes.
- If both partners are found to be carriers of a genetic condition, genetic counseling should be offered. (p. 597)

[back to top](#)

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Policy developed.	03/23	03/23
Semi-annual review. Updated title to reflect V1.2024 version. Overview, coding, reference-table, background and references updated. Throughout policy: replaced “coverage criteria” with “criteria. For Overview: removed “Carrier screening may be	10/23	10/23

Reviews, Revisions, and Approvals	Revision Date	Approval Date
<p>performed...”; added “The majority of professional societies...”; added “Negative carrier screening results...”. For Policy Reference Table; under Expanded Carrier Screening Panels: removed “81243, 81257, 81329, 81443”; removed “Inheritest 500 Plus Panel...”; removed “Comprehensive Carrier...”; removed “GeneSeq...”; removed “Horizon 14 (Natera)”; removed “Horizon 274 (Natera)”; removed “81329, 81336”; added “CFTR Targeted Variants...”; added “Genomic Unity...”; added “DMD Targeted Variants...”; removed “81408”; added “81479”; removed “81403”. For Other Related Policies: added “and Molecular”. For Criteria; under Expanded Carrier Screening Panels: I. and II. added “81336, 81405, 81408, 81479”; added “ACMG recommends...”; for BASIC CARRIER SCREENING PANELS (Cystic fibrosis, Spinal Muscular Atrophy, Fragile X, Hemoglobinopathies, not more than 14 genes): removed “81329”; added “81222, 81223”; removed “should be evaluated...”; added “81329, 81336), may be considered...”; for AMN1 Sequencing and/or Deletion/Duplication and SMN2 Deletion/Duplication Analysis: I. and II. added “0236U”; for Ashkenazi Jewish Carrier Panel Testing: C.7. added “type A”; C.8. added “Type 1”; added C.10-C.13...; for Duchenne and Becker Muscular Dystrophy Carrier Screening: I. and II. removed “81408, 81403”; added “81479”; for DMD Sequencing and/or Deletion/Duplication Analysis: I.B. removed “one of the following.”; removed “male”. For Notes and Definitions: removed “Clinical Considerations...”. For Background and Rationale: removed “American College of Medical Genetics...”; removed “ACMG does not recommend...”; added “Additionally, ACMG recommends...”; added “ACMG does not recommend”; for Basic Carrier Screening Panels (Cystic Fibrosis, Spinal Muscular Atrophy, Fragile X, Hemoglobinopathies, not more than 14 genes): replaced “and” with “includes the”; removed “Fragile X premutation...”; removed “Fragile X premutation carrier...”; for Cystic Fibrosis Carrier Screening: added “Cystic fibrosis carrier screening...”; for CFTR Sequencing and/or Deletion/Duplication Analysis, or Mutation Panel: removed “National Society of Genetic Counselors...”; removed “American College of Obstetricians...”; removed “American College of Medical Genetics...”; for Fragile X Syndrome Carrier Screening: added “reaffirmed in 2020...”; removed “DNA based molecular analysis”; for Duchenne and Becker Muscular Dystrophy Carrier Screening: removed “The recommendation for DMD testing...”; added “Per GeneReviews...”; for DMD Sequencing and/or Deletion/Duplication Analysis: removed “When the familial...”; for General Criteria for Targeted Carrier Screening: removed “Carrier screening is a term...”; removed “National Society of Genetic Counselors...”</p>		
<p>In the criteria for CFTR Sequencing, Deletion/Duplication Analysis, or Mutation Panel, changed the number of tested variants from 23 to 100 and updated background accordingly, consistent with the 2023 ACMG statement on CFTR variant testing.</p>	01/24	



## REFERENCES

1. Deignan JL, Astbury C, Cutting GR, et al. CFTR variant testing: a technical standard of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2020;22(8):1288-1295. doi:10.1038/s41436-020-0822-5
2. Committee Opinion No. 690 (Reaffirmed 2023): Carrier Screening in the Age of Genomic Medicine. *Obstet Gynecol*. 2017;129(3):e35-e40. doi:10.1097/AOG.0000000000001951
3. Committee Opinion No. 691 Summary: Carrier Screening for Genetic Conditions. *Obstet Gynecol*. 2017 (Reaffirmed 2020);129(3):597-599. doi:10.1097/AOG.0000000000001948
4. Gregg AR, Aarabi M, Klugman S, et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG) [published online ahead of print, 2021 Jul 20] [published correction appears in *Genet Med*. 2021 Aug 27;:]. *Genet Med*. 2021;10.1038/s41436-021-01203-z. doi:10.1038/s41436-021-01203-z
5. Prior TW; Professional Practice and Guidelines Committee. Carrier screening for spinal muscular atrophy. *Genet Med*. 2008;10(11):840-842. doi:10.1097/GIM.0b013e318188d069
6. Darras BT, Urion DK, Ghosh PS. Dystrophinopathies. 2000 Sep 5 [Updated 2022 Jan 20]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-20230. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1119/>
7. Fratter C, Dalgleish R, Allen SK, et al. EMQN best practice guidelines for genetic testing in dystrophinopathies. *Eur J Hum Genet*. 2020;28(9):1141-1159. doi:10.1038/s41431-020-0643-7
8. Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. *Genet Med*. 2005;7(8):584-587. doi:10.1097/01.gim.0000182468.22666.dd
9. Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women. *Obstet Gynecol*. 2014;124(1):193-197. doi:10.1097/01.AOG.0000451757.51964.98

[back to top](#)

### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in



developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

**Note: For Medicaid members/enrollees**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take

precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare members/enrollees,** to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2023 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.